Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Applovin Corporation (APP) vs DexCom, Inc. (DXCM) Price & Performance

Applovin CorporationTrade
DexCom, Inc.Trade

Price performance (Past 24H)

Key statistics

Applovin Corporation vs DexCom, Inc. — how do they compare? Applovin Corporation trades at $319.78 (market cap $113.45B), while DexCom, Inc. trades at $88.22 (market cap $33.08B). The key difference: Applovin Corporation is far larger — about 3.4× DexCom, Inc.'s market cap, and DexCom, Inc. is trading nearer its 52-week high, Applovin Corporation nearer its low. Which is the better fit depends on your goals.

APPDXCM
Market Cap
$113.45B$33.08B
Sector
TechnologyHealth
52-Week High
$733.60$89.53
52-Week Low
$318.68$54.84
Enterprise Value
$113.91B$32.53B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Applovin Corporation

AppLovin (APP) trades at $346.80, down 3.32% amid a bearish technical outlook despite strong fundamentals. The stock faces selling pressure after Q2 revenue missed expectations, though it maintains exceptional profitability with 64.58% net margins and 53% YoY revenue growth. Analyst consensus remains bullish with an $569.60 price target, but technical indicators show 18 sell signals versus 2 buys.

The stock presents a growth-at-a-reasonable-price opportunity post-selloff, trading at 26x P/E with 80% analyst buy ratings. Key risks include execution volatility in AI-driven ad pricing and high valuation multiples. Upside depends on Q3 results meeting elevated guidance of 47% growth.

DexCom, Inc.

DXCM trades at $84.75, up 2.08% today and near its 52-week high. The stock shows bullish technical momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $0.70 versus $0.61 expected. Revenue growth accelerated to 13% year-over-year in Q2 2026, driven by G7 system adoption and international expansion. Cash flow from operations improved to $1.44 billion in 2025, supporting financial flexibility.

Outlook remains positive with raised FY2026 guidance and 80% analyst buy ratings, though valuation multiples like P/E of 33.5 suggest premium pricing. Key risks include competitive pressures in glucose monitoring and reliance on reimbursement policies. The consensus price target of $88.65 implies modest upside from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Applovin Corporation

AppLovin provides a software platform for mobile app developers to market, monetize, and analyze their apps. Its AI-powered tools help developers grow their business by connecting them with global advertising networks.

Read more on APP

About DexCom, Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Read more on DXCM